Drugs / VIS954
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06937593 | Mar 2025 → Feb 2026 | — | Otsuka Pharmaceutical Development & Commercialization, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT06212804 | Nov 2023 → Jul 2024 | — | Otsuka Pharmaceutical Development & Commercialization, Inc. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VIS954 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06212804 ↗ |
| Modality | Monoclonal antibody | “VIS954, a monoclonal antibody” NCT06212804 ↗ |
| Route | Subcutaneous | “a single dose of VIS954 or placebo will be administered SC” NCT06212804 ↗ |